Depomed, Santarus sales and marketing update

Depomed disclosed in its 3Q10 earnings that in June 52 lots of 500 mg Glumetza metformin extended release capsules to treat Type II diabetes were recalled and that shipments were temporarily suspended due to the presence of trace amounts of 2,4,6-tribromoanisole (TBA) in bottles containing the tablets. Depomed believes the contamination may have been caused by breakdown of a chemical sometimes applied to wood in pallets used to transport the bottles to the manufacturer in Puerto Rico. Depomed said TBA has been found in food products at levels higher than those detected in the Glumetza bottles and that no serious events associated with TBA have been documented. ...